HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BI 1015550

Also Known As:

(1-(((5R)-2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-5-oxo-6,7-dihydrothieno(3,2-d)pyrimidin-4-yl)amino)cyclobutyl)methanol

Networked: 8 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclobutanes
        BI 1015550: 8
- BI 1015550: 8
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - BI 1015550: 8

Experts

1.	Hesslinger, Christian: 2 articles (01/2022 - 01/2022)
2.	1305-0013 Trial Investigators: 1 article (01/2022)
3.	Azuma, Arata: 1 article (01/2022)
4.	Cottin, Vincent: 1 article (01/2022)
5.	Herrmann, Franziska Elena: 1 article (01/2022)
6.	Maher, Toby M: 1 article (01/2022)
7.	Nickolaus, Peter: 1 article (01/2022)
8.	Richeldi, Luca: 1 article (01/2022)
9.	Stowasser, Susanne: 1 article (01/2022)
10.	Valenzuela, Claudia: 1 article (01/2022)

Related Diseases

1.	Vomiting 01/01/2022 - "In Suncus murinus, PDE4 inhibitors induce emesis, a well-known gastrointestinal side effect limiting the use of PDE4 inhibitors in humans, and the therapeutic ratio of BI 1015550 appeared to be substantially improved compared with roflumilast. "
2.	Idiopathic Pulmonary Fibrosis 01/01/2023 - "Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)." 10/01/2022 - "Phase I and Ic studies were conducted to investigate the safety, tolerability and pharmacokinetics of BI 1015550 in healthy male subjects and patients with idiopathic pulmonary fibrosis (IPF). " 01/01/2022 - "In this placebo-controlled trial, treatment with BI 1015550, either alone or with background use of an antifibrotic agent, prevented a decrease in lung function in patients with idiopathic pulmonary fibrosis. " 01/01/2022 - "In this phase 2, double-blind, placebo-controlled trial, we investigated the efficacy and safety of BI 1015550, an oral preferential inhibitor of the PDE4B subtype, in patients with idiopathic pulmonary fibrosis. " 01/01/2023 - "Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis."
3.	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/01/2023 - "Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)." 01/01/2023 - "BI 1015550, an oral preferential inhibitor of the isoform PDE4B, could express complementary activity to current therapies in IPF and other forms of progressive pulmonary fibrosis. "
4.	Cicatrix (Scar) 12/20/2022 - "Further clinical studies will be conducted in the future to test BI 1015550 in a larger group of people with IPF and other forms of lung scarring that get worse over time, and for a longer time period."
5.	Fibrosis (Cirrhosis) 01/01/2022 - "Oral BI 1015550 was also tested in two well-known mouse models of lung fibrosis (induced by either bleomycin or silica) under therapeutic conditions, and appeared to be effective by modulating various model-specific parameters. "

Related Drugs and Biologics

1.	Phosphodiesterase 4 Inhibitors
2.	Roflumilast
3.	Type 4 Cyclic Nucleotide Phosphodiesterases
4.	Protein Isoforms (Isoforms)
5.	Silicon Dioxide (Silica)
6.	Bleomycin (Blenoxane)

Related Therapies and Procedures

1.	Therapeutics